Stockscreener 앱 받기
0.3473
6.46%
-0.024
시간 외 거래:
.34
-0.0073
-2.10%
Cyclacel Pharmaceuticals Inc 주식(CYCC)의 최신 뉴스
Cyclacel stock plunges to 52-week low of $0.32 amid market challenges - Investing.com
Cyclacel Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Armistice Capital, LLC Increases Stake in Cyclacel Pharmaceutica - GuruFocus.com
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds - The Manila Times
Cyclacel Pharmaceuticals Raises $2.1M Through Warrant Exercise at $0.415 Per Share | CYCC Stock News - StockTitan
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss - MSN
Cyclacel stock plunges to 52-week low of $0.37 amid market challenges - Investing.com Canada
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds - The Manila Times
Cyclacel Pharmaceuticals Raises $2.1M Through Warrant Exercise Deal at $0.415 Per Share | CYCC Stock News - StockTitan
Cyclacel Pharmaceuticals appoints new auditor By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals appoints new auditor - Investing.com India
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update - The Manila Times
Cyclacel Faces Delisting Risk Despite 67% Lower Q3 Loss; Cash Concerns Mount | CYCC Stock News - StockTitan
(CYCCP) Technical Pivots with Risk Controls - Stock Traders Daily
A Data-Based Look At Cyclacel Pharmaceuticals Inc (CYCC) - Stocks Register
Cyclacel stock plunges to 52-week low at $0.6 amid market challenges - Investing.com
Cyclacel stock plunges to 52-week low at $0.74 amid market challenges - Investing.com India
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule - The Manila Times
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - ForexTV.com
Nasopharyngeal Cancer Market Report: Growth Forecast and Key - openPR
Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
CYCCPCyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock Latest Stock News & Market Updates - StockTitan
Cyclacel Pharmaceuticals (CYCC) Price Target Increased by 11.56% to 13.94 - MSN
Cyclacel stock plunges to 52-week low, touches $0.8 By Investing.com - Investing.com Australia
Cyclacel stock plunges to 52-week low, touches $0.8 - Investing.com
CYCCCyclacel Pharmaceuticals, Inc Latest Stock News & Market Updates - StockTitan
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - The Manila Times
Cyclacel stock plunges to 52-week low at $0.95 amid market challenges - Investing.com Australia
Cyclacel stock plunges to 52-week low at $0.95 amid market challenges By Investing.com - Investing.com South Africa
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study - ForexTV.com
Entero Therapeutics (NASDAQ:ENTO) Stock Quotes, Forecast and News Summary - Benzinga
(CYCCP) Trading Report - Stock Traders Daily
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Cyclacel halts dividend on preferred stock - Investing.com
Cyclacel halts dividend on preferred stock By Investing.com - Investing.com Canada
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter - ForexTV.com
Cyclacel Pharmaceuticals May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Benzinga
0.93%
3.55%
자본화:
|
볼륨(24시간):